Please assess the completion status of the following clinical trial:

Trial Title: Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal women 18-50 years of age~2. Requiring gonadrotropin-releasing hormone agonist for any indication except ovulation induction~3. If there is abnormal uterine bleeding, such bleeding is not obviously related to structural defects such as polyps or submucous leiomyomas; subserosal and intramural myomas (International Federation of Gynecology and Obstetrics Classification 3-8 inclusive) are acceptable~Exclusion Criteria:~1. Currently pregnant~2. Recent used of gonadrotropin-releasing hormone agonist~   1. 1 month depot formulation eg leuprolide acetate 3.75, within 90 days~  2. 3 month depot formulation eg leuprolide acetate 11.25 within 180 days~3. Currently has an intrauterine contraceptive device~4. Currently on gonadal steroids (including birth control pills, rings, or implantable or injectable agents)~5. History of breast cancer~6. Currently undergoing ovulation induction~7. History of adverse reactions to gonadal steroids~8. Hemoglobin \<8 mg/dl as measured within 30 days of enrollment (Baseline hemoglobin is standard of care for patients initiating gonadrotropin-releasing hormone agonist therapy)~9. Weight above \>250 lbs~10. Has a known submucous leiomyoma ( International Federation of Gynecology and Obstetrics Class type 0, 1, 2)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- medroxyprogesterone acetate (Type: ACTIVE_COMPARATOR): None
- control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).